Expression of the breast and ovarian cancer gene BRCA1 is regulated at both the transcriptional and post-transcriptional levels. We found that the expression of the BRCA1 protein may also be regulated at the translational level. In addition to an AUG start codon at position 1, BRCA1 mRNA has a second in-frame AUG (+17) that acts as an alternative start codon to generate a novel BRCA1 protein that lacks the ®rst 17 amino acids (DBRCA1(17aa)). We fused cDNAs encoding the second exon of BRCA1 of the wild-type BRCA1 gene (wt-BRCA1) and a mutated BRCA1 gene (mt-BRCA1), in which the ®rst initiation site and its Kozak consensus sequence were abolished, with the nucleophosmin (NPM) reporter gene and used them for in vitro and in vivo translation assays. In both systems, the wt-BRCA1-NPM constructs produced two distinct proteins (18 and 16 kD) begun from the ®rst and second AUGs. The mt-BRCA1-NPM constructs produced only the shorter 16-kD protein lacking the ®rst 17 amino acids of the BRCA1 gene. Next, we analysed the N-terminal protein sequence of puri®ed BRCA1 protein from normal thymocytes and found two dierent BRCA1 proteins, derived from translation of the ®rst and second in-frame AUGs. Thus, BRCA1 protein expression can be regulated at the translation level in normal cells. Characterization of DBRCA1(17aa) may shed light on the function and regulation of BRCA1 in normal cells as well as the pathogenesis of breast and ovarian cancers.
BRCA1 gene expression is regulated at multiple levels. In addition to inactivation of the BRCA1-gene structure, BRCA1 can be extensively regulated at the transcriptional level. Two promoters, a and b, direct the transcription of BRCA1 mRNA to generate two distinct transcripts (Xu et al., 1995) . The a promoter is shared by the adjacent NBR2 gene and operates bidirectionally. Multiple cis-and transacting factors have been shown to regulate the level of transcription of the BRCA1 gene (Thakur and Croce, 1999; Xu et al., 1997a) . In addition, a truncated BRCA1 pseudogene composed of exons 1 and 2 of BRCA1, located between the NBR2 and NBR1 genes, was recently identi®ed (Brown et al., 1996; Xu et al., 1995 Xu et al., , 1997b . The BRCA1 gene has two distinct transcriptional start sites, one of which excludes the ®rst exon of the gene. The two transcripts are generated by the alternative use of a dual promoter and alternative splicing (Xu et al., 1995) . More complexity is achieved through the generation of several isoforms of BRCA1 as a result of alternative splicing of exons 1 to 11. These isoforms may have dierent biological functions. In fact, mRNA of BRCA1 that lacks exon 11 sequences will encode proteins that lack two putative localization signals and are unable to interact indirectly with hRAD51, a homologue of RecA involved in DNA damage-repair processes in bacteria (Lu et al., 1996; Thakur et al., 1997) . Two other splicing variants, BRCA1a/p110 and BRCA1b/p100, have also been reported; the overexpression of BRCA1a/p110 can accelerate apoptosis in human breast cancer cell lines and promote transcription. This ®nding demonstrates that the BRCA1 protein contains, in addition to the previously described BRCT repeat at the carboxy-terminal region, that is associated with DNA repair (Bork et al., 1997; Callebaut and Mornon, 1997) , a novel transcriptional activation domain at its N-terminal region.
Germline mutations within the BRCA1 gene are responsible for approximately 85% of familial breast and ovarian cancers and approximately 50% of familial breast cancers alone (Castilla et al., 1994; Easton et al., 1993; Ford et al., 1994; Friedman et al., 1994; Miki et al., 1994) . However, the deregulated expression of BRCA1 has been recently documented in familial breast cancer and in a subset of sporadic breast cancers. Although mutations are rare in sporadic breast and ovarian cancers, the BRCA1 protein is lost in a large percentage of high-grade breast and ovarian cancers, and this latter ®nding correlates with a poor prognosis Wilson et al., 1999) . In addition, BRCA1 mRNA levels are markedly decreased during the transition from carcinoma in situ to invasive breast cancer (Thompson et al., 1995) and are downregulated in a variety of histologic types of breast carcinomas (Magdinier et al., 1998) . Hypermethylation of the BRCA1 promoter, which could inhibit transcription, has been observed in sporadic breast and ovarian cancers (Catteau et al., 1999; Dobrovic and Simpfendorfer, 1997; Mancini et al., 1998) .
In the process of screening BRCA1 185delAG mutations in Ashkenazi Jewish women with breast cancer in the New York metropolitan area, we used oligoprimers complementary to the intron sequences anking exon 2 to amplify the entire exon 2 for genetic analysis (Figure 1a) . After PCR ampli®cation, the DNAs of breast carcinomas were subjected to SSCP analysis (Figure 1b) . After initial screening of 32 patients, one patient was found to have an abnormal migrating pattern. Subcloning and sequencing analyses repeatedly showed BRCA1-related sequences carrying a G to A transition at the third position of the ®rst AUG and an A to G transition at the 71 position ( Figure 1c) . A series of constructs carrying the 185delAG deletion, a frequent deletion mutation in Jewish women with breast cancer, were also observed. Search of the database revealed that the ®rst allele had a 100% match with the sequence of exon 2 of a newly identi®ed BRCA1 pseudogene (Figure 1a) . Therefore, these two transitions in and near the ®rst AUG represent a`pseudomutation' rather than a novel germline mutation in the BRCA1 gene. The presence of a pseudomutation could complicate the genetic testing of BRCA1 gene, since it is often dicult to Figure 1 Genomic structure and sequence analysis of exon 2 from the wild-type BRCA1 gene and the BRCA1 pseudogene. (a) Genomic structure at the 5' end of the BRCA1 gene. (b) SSCP analysis of exon 2 of BRCA1 gene. An arrow indicates abnormal migrating bands. Single-strand conformational polymorphism (SSCP) analysis was conducted according to an adapted version of a previously reported method (Gaidano et al., 1991) . PCRs were carried out in 10 ml reaction volumes with at least 10 ng of DNA (Inghirami et al., 1994) as a template, 1 pmol of each primer, 25 mM MgCl 2 , 50 mM dNTP with or without the presence of of 1 mCi of [ a-32 P]dCTP (NEN Life Science, Boston, MA, USA; speci®c activity, 3000 Ci/mmol), 1 U of Taq DNA polymerase and 1 ml of the 106 PCR buer (50 mM KCL, 10 mM Tris-HCL pH 9.0 and 0.1% Triton X-100) supplied by the manufacturer (Promega, Madison, WE, USA). The mixture was heated for 3 min at 948C, followed by 35 cycles of 30 s at 948C, 1 min at 558C, and 1 min at 728C, followed by a ®nal extension of 7 min at 728C. Two speci®c oligoprimers were synthesized against the 5'-to-3' intron of exon 2 of the BRCA1 gene (forward primer (FP): 5'-GAA GTT GTC ATT TTA TAA ACC TTT-3' and reverse primer (RP): 5'-GTA TGT AAG GTC AAT TCT GTTC-3'). PCR products were cloned directly into the pCRII vectors according to the manufacturer's recommendations (Invitrogen, Carlsbad, CA, USA). (c) Sequence analysis of exon 2 of BRCA1 gene. The upper left panel shows the wild-type sequence, and the lower left shows the sequence with a 2-base pair deletion at the 7185 position. The upper right panel shows the sequence surrounding the normal initiation codon, and the lower right panel shows the sequence of`mutated' initiation codon from the BRCA1 pseudogene dierentiate a disease-causing mutation from a pseudomutation after PCR ampli®cation. Mutations in the initiation codon and other regions of exon 1 and 2 have been reported (Castilla et al., 1994; Friedman et al., 1994) . However, it is unclear whether these mutations within exon 2 occurred in the BRCA1 or resulted from the ampli®cation of the pseudoBRCA1 gene.
Given the presence of a G to A transition in the AUG start codon derived from this pseudogene, we hypothesized that this would have been a diseasecausing mutation if it were in the`real' BRCA1 gene. Therefore, we examined the potential regulatory elements involved in the translational initiation of BRCA1 protein. The nucleotide sequence at the 5' end of BRCA1 mRNA is shown in Figure 2a . Careful examination of these sequences revealed a second inframe AUG located 48 nucleotides downstream of the ®rst AUG. Both AUGs are surrounded by good consensus Kozak sequences except for a C rather than a G in the +4 position in the second AUG ( Figure 2c ). If the second AUG is also used as an alternative start codon, then a protein lacking the ®rst 17 amino acids BRCA1 (17aa) could be produced, and this protein may have a dierent function from the wild-type BRCA1. Since the ®rst 17 amino acids are highly conserved among BRCA1 genes of dierent species, their deletion may result in loss of function. The importance of this deletion is also suggested by its close proximity to the BRCA1 RING motif.
To test this hypothesis, we examined the role of both AUGs in the translational initiation of the BRCA1 protein. Because BRCA1 encodes a very large (1863aa) protein, the dierence between two proteins diering only in the ®rst 17aa could not be resolved on a regular SDS ± PAGE gel. Therefore, we replaced the 3' end of the BRCA1 gene with a short peptide corresponding to the last 107 amino acids of the nucleophosmin (NPM) gene (Chan et al., 1989) . This peptide is speci®cally recognized by a polyclonal antibody. The schematic of the two constructs is shown in Figure 3a . The wild-type construct containing DNA fragments representation encoding the ®rst 26 amino acids was fused to the NPM peptide by a GC-rich sequence segment encoding 17 glycine-rich amino acids. The mt-BRCA1/NPM construct was similarly designed, being identical to the wild-type except for G-to-A and A-to-G nucleotide transitions at positions +3 and 71 (exon 2 of the BRCA1 pseudogene). In vitro translation from the wt-BRCA1/NPM mRNA construct showed two proteins of 18 and 16 kD, which must have corresponded to the translational initiation sites from the ®rst and second AUGs. The mt-BRCA1/NPM expression vector produced only the 16 kD protein (Figure 3b ). Western blot analysis from in vitro translated protein revealed that both the 18 kD and 16 kD proteins contained the expected NPM peptide (Figure 3c ), con®rming the hypothesis that the second AUG could also be recognized as a start site for protein translation.
To test whether both AUGs could function as initiation codons in vivo, the above constructs were subcloned in eucaryotic expression vectors that use the cytomegalovirus (CMV) promoter to direct downstream transcription (Figure 3a) . Both wt-and mt-BRCA1-NPM constructs were transfected into 293T cells. Both the 18 and 16 kD proteins were detected after transfection with the wt-BRCA1/NPM construct. In contrast, only the 16 kD protein was detected from the mt-BRCA1/NPM construct (Figure 3d ), demonstrating that the G-to-A transition completely abolished its role in translational initiation. To test whether the dierence between the 18 and 16 kD proteins was due to the ®rst 17 amino acids, we analysed the same cellular extracts by immunoprecipitation followed by a Western blot analysis using a speci®c antibody against the ®rst 20 amino acids of the BRCA1 protein, D20. The 18-kD protein was detected upon translation with the wild-type construct, but not from the mt-BRCA1-NPM (Figure 3e ), con®rming that the dierence between the 18 and 16 kD proteins was due to the loss of the ®rst 17 amino acids of the BRCA1 protein.
To determine whether DBRCA1(17aa) isoform was present also in vivo and that it was not a spurious initiation originating from the use of arti®cial expression vectors, we immunoprecipitated the BRCA1 protein from a thymus homogenate by using a combination of two polyclonal antibodies (K18 and C20) directed against the N-and C-terminus of the molecule, respectively. We decided to use normal thymocytes because thymus tissue displays high levels of BRCA1 in RNA transcripts (Xu et al., 1995) . The immunoprecipitated material showed a 220 kD protein band that was immunoreactive by Western blotting with a MAb to the BRCA1 protein, corroborating the speci®city of the immunoprecipitation and the presence of BRCA1 protein in the cell homogenate. The amino acid sequence analysis of the electrotransferred 220 kD protein band revealed two N-terminal sequences in accordance with the presence of the two initiation signals.
The major sequence obtained, LRVEEVQNVXNAM (N-terminus 1; Figure 4b ), corresponded to amino acids 6 ± 18 of the BRCA1 sequence deduced from the cDNA. A minor sequence, MQKIXXXXI (N-terminus 2; Figure 4b) , representing approximately 20% of the major sequence, started at the second putative initiation site, indicating the presence of a DBRCA1(17aa) isoform in vivo. The Nterminus 1 began ®ve amino acids after the putative Nterminal Met predicted by the cDNA sequence. Whether this proteolysis occurs in vivo as a result of a post-translational processing or whether it represents a technical artifact of the preparation remains to be Schematic diagram of the wt-BRCA1/NPM and the mt-BRCA1/NPM constructs. The wt-BRCA1/NPM construct contains the DNA fragment encoding the ®rst 26 amino acids of BRCA1, which is fused to the last 107aa of the NPM gene by a GC-rich linker encoding a glycine-rich 17 amino acid hinge. BRCA1/nucleophosmin (NPM) chimeric expression vectors were constructed by using a recombinant PCR approach with two sequential PCRs. Two independent PCRs were carried out to generate PCR products corresponding to the second exon of BRCA1 and the last 107aa end C-terminus of NPM. Both PCR products carried an overlapping hinge DNA sequence (BRCA1-hinge and hinge-NPM) for the ®nal recombinant PCR. The BRCA1-hinge PCR products were generated by using the BRCA1 (FP) 5'-TAA GTT CAT TGG AAC AGAA and a BRCA1 (RP) equipped with a speci®c hinge sequence 5'-GGA GCC GCC GCC GCC AGA ACC ACC ACC ACC AGC CCA GAT GGG ACA CTC TA). The hinge-NPM PCR products were generated by using speci®c oligonucleotides primers recognizing the NPM gene (NPM (RP) 5'-TTA AAG AGA CTT CTT CCA CT) and the forward primer was equipped with an overlapping hinge DNA sequence (NPM (FP) 5'-GGC GGC GGC GGC TCC GGT GGT GGT GGT TCT GCG CCA GTG AAG AA). To generate the hinge-NPM PCR products, 1 mg of cDNA from normal thymocytes was subjected to PCR ampli®cation. Both PCRs were carried out using a`touch down' PCR (a denaturing cycle of 958C for 3 min was followed by four cycles of 15 s at 948C, 1 min at 648C and 1 min at 728C; four cycles of 15 s at 948C, 1 min at 628C, and 1 min at 728C; 30 cycles of 15 s at 948C, 1 min at 608C, and 1 min at 728C and a ®nal extension at 728C for 10 min). For the recombinant PCR, 50 ng of the puri®ed BRCA1-hinge and hinge-NPM PCR products were incubated for 30 min at 628C in the presence of Taq polymerase and PCR buer containing 1.5 mM MgCl 2 . This initial cycle was subsequently followed by four additional cycles (denaturing at 948C and annealing-extension at 728C), which were followed by 30 cycles of ampli®cation (denaturing at 948C, annealing at 578C, and extension at 728C), followed by a ®nal extension of 7 min at 728C in the presence of 20 pM each of FP-BRCA1 and RP-NPM oligoprimers. PCR products were then gel separated and extracted DNAs were ligated into the pCRII vector. Cloned DNAs were sequenced with a SP6 oligoprimer and automated DNA sequencer (ABI 373, Applied Biosystems, Perkin-Elmer Cetus). (b) In vitro translation of proteins from the wt-BRCA1/NPM and mt-BRCA1/ NPM constructs. In vitro transcription (1 mg of each plasmid) and translation were carried out according to the manufacturer's protocol (Promega) using a rabbit reticulocyte system and [ 35 S]methionine (NEN Life Science, Beverly, MA, USA). Newly synthesized proteins were analysed on a 15% SDS polyacrylamide gel. (c) Western blot analysis of in vitro translated protein from the wt-BRCA1/NPM construct. In vitro translate products were electrophoresed in 15% SDS ± PAGE gel and transferred onto nitrocellulose membranes. Filters were ®rst blocked with 5% low-fat milk in PBS with 0.1% Tween 20 and subsequently incubated with anti-NPM (1 : 250; kindly provided by Dr PK Chan (Chan et al., 1989) ) (lane 1) or with rabbit serum as a control (lane 2) for 1 h at room temperature. After being washed three times, the ®lters were incubated with HRP-conjugated goat antirabbit Ab (1 : 2000: Amersham) for 1 h at room temperature, followed by chemiluminescence detection (ECL, Amersham). (d) Western blot analysis after transfection of wt-BRCA1/NPM and mt-BRCA1/NPM constructs into 293T cells. 293T cells were cultured in 6-well Falcon plates (Becton Dickison, Mountain View, CA, USA) and transfected with 1 mg of puri®ed plasmid DNAs (wt-BRCA1/NPM and mut-BRCA1-NPM) with 25 ml of eectene following the manufacturer's recommendations (Qiagen Inc, Valencia, CA, USA). Cells were subsequently incubated overnight, washed with phosphate-buered saline (PBS) and cultured in RPMI-1640 with 10% fetal calf serum with 1 mg/ml of puromycin (Sigma, St Louis, MO, USA) for 4 days. Transfected 293T cells (1610 6 /sample) were then washed twice with PBS, lysed with 20 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Triton X100, 5 mM EDTA, 1 mM Na 3 VO 4 , and 1 mM PMSF and centrifuges. Ten micrograms of total cell protein lysates were electrophoresed in 15% SDS ± PAGE gel and transferred onto nitrocellulose membranes. Filters were incubated with anti-NPM and developed as described above. (e) Immunoprecipitation and Western blot analysis of transfected 293T cells. Total cell protein lysates of wt-BRCA1-NPM and mt-BRCA1-NPM transfected 293T cells were ®rst incubated with 20 ml/ml of protein G sepharose (1 : 1; 1 h) and then the pre-cleared supernatants were reacted with 2 mg/ml of rabbit anti-NPM for 2 h at 48C. After extensive washes, the immunoprecipitated complexes were separated on a 15% SDS gel and then transferred onto the nitrocellulose membrane (wt-BRCA1-NPM (lane 1) mt-BRCA1-NPM (lane 2)). Filters were incubated with the anti-BRCA1 Ab speci®cally recognizing the ®rst 20 amino acids at the Nterminus (D10) (Santa Cruz, Santa Cruz, CA, USA), followed by HRP-conjugated goat anti-rabbit and chemiluminescence detection (ECL) elucidated. Notably, this second sequence starts at an amino acid residue that corresponds to the reported cleavage site of elastase (Colizan et al., 1995) . However, six additional putative cleavage sites for the elastase are also present within the ®rst 17aa of BRCA1, including an Ala at position 16 that upon elastase cleavage might result in a peptide with identical N-terminal sequence as the one originated from the second initiation site. However, the absence of additional N-terminal amino acid sequences suggests that the presence of these two N-terminal sequences is a consequence of two initiation signals and not a result of multiple elastase cleavages. Our data strongly support the hypothesis that a peptide BRCA1 starting from a second in-frame AUG is expressed in normal thymocytes.
Here, we have provided evidence to support the hypothesis that a second in-frame AUG in BRCA1 mRNA can be recognized as an initiation codon. Such recognition generates a novel isoform of BRCA1 protein, DBRCA1(17aa). From our in vitro and in vivo evidence, we can speculate that the expression of BRCA1 protein is probably also regulated at the level of translation, adding another level of complexity to the already complicated picture of the regulation of the BRCA1 gene expression.
Located on chromosome 17q21, BRCA1 is a large gene, with 22 exons distributed over approximately 100 kB of genomic DNA (Hall et al., 1990; Miki et al., 1994) . The full-length BRCA1 protein product is a 220 kD nuclear phosphoprotein with 1863 amino acids (Chen et al., 1996) . A short region at the 5' end of the BRCA1 protein constitutes a 7-cysteine, 1-histidine RING motif that interacts with BARD1 (BRCA1-associated RING domain), a recently described RING protein (Wu et al., 1996) . The BRCA1 RING motif also interacts with BAP1 (Jensen et al., 1998) , a novel ubiquitin hydrolase that can enhance BRCA1-mediated cell-growth suppression. The same region seems to participate in vitro in protein-protein interactions with E2F transcription factors, cyclins, and cyclin-dependent kinases (Wang et al., 1997) . Biochemical studies have shown that the C-terminus of BRCA1 interacts with hRAD51, a human homolog of bacterial recA, a protein involved in homologous chromosome recombination and postradiation DNA repair (Scully et al., 1997b) . Co-localization studies have also demonstrated that BRCA1 accumulate into discrete subnuclear foci termed`BRCA nuclear dot' and associate with hRAD50, BARD1 and hRAD51 implying an important functional interaction of these molecules (Jin et al., 1997; Scully et al., 1997b; Zhong et al., 1999) . Treating cultured cells with ionized radiation leads to the hyperphosphorylation of the BRCA1 protein, which is mediated by the protein kinase ATM (mutated in ataxia telengiectasia) (Cortez et al., 1999) , and disappearance of BRCA1 nuclear dots (Runer and Verma, 1997; Scully et al., 1997a; Thomas et al., 1997) .
Moreover several lines of information have demonstrated that BRCA1 plays an important role in the regulation of gene transcription. It has been demonstrated that the C-terminus of BRCA1 contains a transcriptional activation domain (Chapman and Verma, 1996; Haile and Parvin, 1999; Monteiro et al., 1996) that can interact with components of the histone deacetylase complex (Yarden and Brody, 1999) . Recent biochemical studies have also shown that BRCA1 co-elutes with the RNA polymearase II holoenzyme complex (Scully et al., 1997a) and the CBP/P300 co-activator (Cui et al., 1998) , and it also co-immunoprecipitates with p53 and regulates p53-dependent gene expression (Ouchi et al., 1998; Zhang et al., 1998) .
The functional signi®cance of DBRCA1(17aa) is unclear. However, Meza and co-authors recently have demonstrated that the RING ®nger motif of BRCA1 is not a stable structural domain but it is instead part of a larger domain comprising residues 1 ± 109 (Meza et al., 1999) . Thus, the loss of the ®rst 17aa might seriously compromise and/or weaken the interactions of BRCA1 with its functional interactors, such as BARD1 and BAP1, impairing the formation of the BRCA1/BARD1/hRAD51 DNA repair complex. The loss of this complex can lead to S phase retardation . Cells obtained by homogenization of normal thymus tissue were ®rst lysed (at 48C for 30 min with 50 mM Tris-HCl buer (pH 7.5) containing 250 mM NaCl, 0.1% Triton X-100, 1 mM EDTA, 1 mM DTT and a cocktail of protease inhibitors (1 mM PMSF, 1 mg/ml leupeptin, 10 mg/ml soybean trypsin inhibitor and 1 mg/ml aprotinin). Cell lysates were immunoprecipitated with magnetic beads (Dynabead, Dynal, Oslo, Norway) coated with a mixture of the following polyclonal anti-BRCA1 antibodies: K18, against an epitope localized at amino acid residues 70 ± 89 in the N-terminal of the molecule (Santa Cruz, USA), and C20, recognizing an epitope localized at residues 1843 ± 1862 in the C-terminus of the BRCA1 molecule (Santa Cruz, USA). After extensive washes, the immunoprecipitated material was extracted by boiling the magnetic beads with 26 concentrated Laemnli sample buer and subsequently separated by SDS ± PAGE on a 5 ± 20% acrylamide gradient gel. After electrophoresis, proteins were electrotransferred onto a polydivinylidene di¯uoride (PVDF) membrane (Immobilon P, Millipore Corp., Bedford, MA, USA) with 10 mM cyclohexyl aminopropane sulforic acid (CAPS; Sigma) buer, pH 11.0, containing 10% methanol. A part of the membrane was subjected to Western blot analysis and immunoreacted with the MAb anti-BRCA1 (Ab-1; Calbiochem), followed by HRP-labeled anti-mouse IgG (Amersham), and the immunoreactivity was detected by chemiluminescence (ECL). (b) N-terminal amino acid sequence analysis. The major (N-terminus 1) and minor (N-terminus 2) sequences obtained by automatic Edman degradation of the 220 kD protein band are compared with the BRCA1 sequence deduced from the cDNA. To determine the amino-terminal sequence, immunoprecipitated proteins transferred to the PVDF membrane were visualized by staining with 0.1% Coomassie Blue R-250 in 50% methanol. The protein band corresponding to the 220 kD molecular mass was excised from the membrane and analysed by automated Edman degradation (Matsudaira, 1987 ) with a 477A protein sequencer (Applied Biosystems; Foster City, CA, USA) and, in the appropriate context, may possibly encourage the cellular transformation (Irminger-Finger et al., 1999) . In fact, the functional inactivation of BARD1 has been associated with cell proliferation and cell dierentiation defects (Irminger-Finger et al., 1998) and may lead to premature terminated transcripts and potentially deleterious proteins (Kleiman and Manley, 1999) . In addition, DBRCA1(17aa) may possibly act as a transdominant modulator, blocking or modulating some function of wild-type BRCA1, or interfere with interaction with p53 (Chai et al., 1999; Cressman et al., 1999; Ouchi et al., 1998; Xu et al., 1999) . Finally, we can speculate that the expression of dierent isoforms may allow the activation of speci®c pathways coupled to unique dierentiation stages and/ or functioning in unique tissues. Toward this end, we can hypothesize that DBRCA1(17aa) will preferentially act as DNA transcription factor possibly associating itself to known transcripional coactivators, such as CBP/p300 (Pao et al., 2000) . For example, in the thymus, the full length BRCA-1 might be involved in the assembly and/or regulation of T-cell receptor gene rearrangements, an operation which requires a DNA repair machinery, and DBRCA1(17aa) products might indirectly participate in thymic cell death and perhaps thymic selection allowing the preferential transactivation of p53. Finally, we can speculate that DBRCA1(17aa) may be speci®cally translated in a tissue-speci®c manner and interacts with speci®c factors mediating cell dierentiation and development. Whether the loss of functional BRCA1 predisposes an individual to develop breast and ovarian cancer but not other neoplasms remains an open question. Understanding the regulatory processes at the level of translation may shed light on the mechanisms of BRCA1 in breast and ovarian carcinogenesis.
